Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Kapoun · SciRah

Researcher profile · Semantic Scholar

A. Kapoun

Share profile

A. Kapoun — researcher profile on SciRah

h-index: 41
Works: 147
Citations: 6,466

Most-cited papers

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
A. Gurney, F. Axelrod, Chris Bond, Jennifer A. Cain +19 more
2012Proceedings of the National Academy of Sciences of the United States of America599 citations Open access
Semantic Scholar
Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer
Jing S. Lim, Alvaro Ibaseta, Marcus M. Fischer, B. Cancilla +16 more
2017Nature347 citations Open access
Semantic Scholar
Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
W. Yen, M. Fischer, F. Axelrod, Chris Bond +14 more
2015Clinical Cancer Research239 citations Open access
Semantic Scholar
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
R. Ferrarotto, Y. Mitani, L. Diao, I. Guijarro +16 more
2016Journal of Clinical Oncology222 citations Open access
Semantic Scholar
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
A. Jimeno, M. Gordon, R. Chugh, W. Messersmith +8 more
2017Clinical Cancer Research161 citations
Semantic Scholar
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
David C. Smith, P. Eisenberg, G. Manikhas, R. Chugh +6 more
2014Clinical Cancer Research152 citations
Semantic Scholar
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer
J. Diamond, C. Becerra, D. Richards, A. Mita +11 more
2020Breast Cancer Research and Treatment136 citations Open access
Semantic Scholar
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death
M. Fischer, B. Cancilla, V. P. Yeung, F. Cattaruzza +13 more
2017Science Advances133 citations Open access
Semantic Scholar
Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
M. Fischer, W. Yen, A. Kapoun, Min Wang +4 more
2011Cancer Research128 citations
Semantic Scholar
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
R. Ferrarotto, G. Eckhardt, A. Patnaik, Patricia M. Lorusso +5 more
2018Annals of Oncology124 citations Open access
Semantic Scholar
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
S. Davis, D. Cardin, S. Shahda, H. Lenz +7 more
2019Investigational new drugs104 citations Open access
Semantic Scholar
Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.
C. Chartier, J. Raval, F. Axelrod, Chris Bond +18 more
2016Cancer Research101 citations
Semantic Scholar
A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
K. Moore, Camille C. Gunderson, P. Sabbatini, D. Mcmeekin +8 more
2019Gynecologic Oncology95 citations Open access
Semantic Scholar
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Z. Hu, J. Bendell, A. Bullock, N. Loconte +18 more
2019Cancer Medicine78 citations Open access
Semantic Scholar
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors
A. Jimeno, K. Moore, M. Gordon, R. Chugh +7 more
2018Investigational new drugs78 citations
Semantic Scholar
First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors.
David C. Smith, L. Rosen, R. Chugh, J. Goldman +7 more
201378 citations
Semantic Scholar
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
M. McKeage, D. Kotasek, B. Markman, M. Hidalgo +7 more
2018Targeted oncology70 citations
Semantic Scholar
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
David C. Smith, R. Chugh, A. Patnaik, K. Papadopoulos +6 more
2018Investigational new drugs68 citations Open access
Semantic Scholar
Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
W. Yen, M. Fischer, Mark J. Hynes, Jing-Jiang Wu +9 more
2012Clinical Cancer Research66 citations Open access
Semantic Scholar
Phase 1b study of Wnt inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer (mPDAC)
Efrat Dotan, D. Cardin, H. Lenz, W. Messersmith +10 more
2020Clinical Cancer Research56 citations Open access
Semantic Scholar
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
N. Mettu, S. Ulahannan, J. Bendell, I. Garrido-Laguna +6 more
2021Clinical Cancer Research52 citations Open access
Semantic Scholar
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations
Marcus M. Fischer, V. P. Yeung, F. Cattaruzza, Rajaa A. Hussein +10 more
2017Scientific Reports51 citations Open access
Semantic Scholar
Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors
L. Petrillo, D. Wolf, A. Kapoun, Nicholas Wang +11 more
2012Breast Cancer Research and Treatment44 citations Open access
Semantic Scholar
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
E. O'Reilly, V. Sahai, J. Bendell, A. Bullock +16 more
201743 citations
Semantic Scholar
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs
Ming-Jun Zhang, Michael Haughey, Nai-Yu Wang, K. Blease +20 more
2020PLoS ONE41 citations Open access
Semantic Scholar
Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)
J. Bendell, G. Eckhardt, H. Hochster, V. Morris +8 more
201630 citations
Semantic Scholar
Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies
Carla Casulo, J. Ruan, N. Dang, L. Gore +10 more
201629 citations
Semantic Scholar
Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types
Cecile Chartier, J. Raval, F. Axelrod, Chris Bond +19 more
201524 citations
Semantic Scholar
A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.
A. Jimeno, M. Gordon, R. Chugh, W. Messersmith +7 more
201422 citations
Semantic Scholar
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
W. Messersmith, S. J. Cohen, S. Shahda, H. Lenz +14 more
201620 citations Open access
Semantic Scholar
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
M. Pietanza, A. Spira, R. Jotte, S. Gadgeel +11 more
201520 citations
Semantic Scholar
Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).
M. Mita, C. Becerra, D. Richards, A. Mita +11 more
201619 citations
Semantic Scholar
1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
D. Daniel, C. Rudin, L. Hart, D. Spigel +13 more
201717 citations Open access
Semantic Scholar
Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.
David C. Smith, M. Gordon, W. Messersmith, R. Chugh +7 more
201317 citations
Semantic Scholar
Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models
P. Yeung, L. Beviglia, B. Cancilla, C. Dee-Hoskins +7 more
201416 citations
Semantic Scholar
Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).
R. O'Cearbhaill, D. Mcmeekin, G. Mantia-Smaldone, C. Gunderson +9 more
201614 citations
Semantic Scholar
Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
Efrat Dotan, D. Cardin, H. Lenz, W. Messersmith +8 more
2019Journal of Clinical Oncology13 citations
Semantic Scholar
Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
C. Weekes, J. Berlin, H. Lenz, B. O'Neil +14 more
201613 citations Open access
Semantic Scholar
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.
M. Hidalgo, P. Cooray, A. Carrato, M. Jameson +8 more
201613 citations
Semantic Scholar
A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.
M. Hidalgo, P. Cooray, M. Jameson, A. Carrato +7 more
201510 citations
Semantic Scholar
Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
E. O'Reilly, L. Smith, J. Bendell, J. Strickler +9 more
201510 citations
Semantic Scholar
A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors.
A. Tolcher, R. Chugh, Glenda Chambers, V. Thorpe +5 more
201210 citations
Semantic Scholar
Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
E. O'Reilly, L. Smith, J. Bendell, Fatima A. Rangwala +8 more
20149 citations
Semantic Scholar
Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.
B. Cancilla, Jennifer A. Cain, Min Wang, L. Beviglia +6 more
20138 citations
Semantic Scholar
111P Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
G. Sarikonda, B. Wallace, C. Wiesner, Sunil Krishnan +2 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.
S. L. Davis, P. LoRusso, Lu Xu, A. Kapoun +4 more
20137 citations
Semantic Scholar
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
A. Chiang, C. Rudin, A. Spira, R. Jotte +11 more
20166 citations
Semantic Scholar
Abstract 4233: Wnt pathway antagonist ipafricept (FZD8-Fc, OMP-54F28) inhibits tumor growth and reduces tumor-initiating cell frequency in ovarian patient-derived xenograft models
M. Fischer, W. Yen, Chunhua Zheng, Randall Henner +8 more
20156 citations
Semantic Scholar
Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency
W. Yen, M. Fischer, G. Argast, B. Wallace +6 more
20156 citations
Semantic Scholar
A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.
S. L. Davis, D. Cardin, S. Shahda, H. Lenz +7 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Dupont×23
Invite
J. Dupont — researcher profile on SciRah
Lu Xu×20
Invite
Lu Xu — researcher profile on SciRah
R. Stagg×15
Invite
R. Stagg — researcher profile on SciRah
T. Hoey×14
Invite
T. Hoey — researcher profile on SciRah

×13

Invite

J. Lewicki — researcher profile on SciRah

Invite

A. Gurney — researcher profile on SciRah

Invite

W. Yen — researcher profile on SciRah

Invite

M. Fischer — researcher profile on SciRah

Jennifer A. Cain×9

Invite

Jennifer A. Cain — researcher profile on SciRah

R. Brachmann×9

Invite

R. Brachmann — researcher profile on SciRah

Invite

B. Cancilla — researcher profile on SciRah

Invite

Min Wang — researcher profile on SciRah